Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $18.13 and last traded at $19.17, with a volume of 28891 shares traded. The stock had previously closed at $19.62.
Analysts Set New Price Targets
Several analysts have issued reports on DNTH shares. Raymond James raised shares of Dianthus Therapeutics to a "moderate buy" rating in a research note on Thursday, December 12th. Oppenheimer lifted their price target on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an "outperform" rating in a research note on Monday, November 11th. TD Cowen assumed coverage on shares of Dianthus Therapeutics in a research note on Friday, December 20th. They set a "buy" rating for the company. Finally, HC Wainwright reaffirmed a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $46.83.
Check Out Our Latest Stock Report on Dianthus Therapeutics
Dianthus Therapeutics Price Performance
The company has a market capitalization of $711.22 million, a PE ratio of -9.61 and a beta of 1.82. The company's fifty day moving average is $22.56 and its 200-day moving average is $25.05.
Hedge Funds Weigh In On Dianthus Therapeutics
Institutional investors have recently bought and sold shares of the business. R Squared Ltd purchased a new position in Dianthus Therapeutics during the fourth quarter valued at approximately $26,000. Quest Partners LLC increased its holdings in Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company's stock valued at $31,000 after buying an additional 1,124 shares during the period. KLP Kapitalforvaltning AS purchased a new position in Dianthus Therapeutics in the fourth quarter worth $33,000. KBC Group NV purchased a new position in Dianthus Therapeutics in the fourth quarter worth $35,000. Finally, BNP Paribas Financial Markets purchased a new position in Dianthus Therapeutics in the fourth quarter worth $59,000. 47.53% of the stock is owned by hedge funds and other institutional investors.
About Dianthus Therapeutics
(
Get Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Read More
Before you consider Dianthus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.
While Dianthus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
